Junshi Bio wins shareholder nod for Shanghai tech board IPO
Shanghai Junshi Biosciences’ shareholders have given the green light to the firm’s proposal to float primary stock on Shanghai’s new Nasdaq-style board, according to an exchange filing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts